We explain new findings in everyday language, with dates and links to sources.
Mounjaro, which contains the active ingredient tirzepatide, is injected under the skin — including into the abdomen when there is a noticeable layer of fat. We explain what is known about injection sites and why the medicine must not be injected into a muscle.
The aim of treatment is not to stop eating. The return of appetite is not a reason to take extra injections. We explain what is known about how Semaglutide works and why more medicine does not mean better treatment.
A new analysis from September 2026 concerns body composition and physical function during obesity treatment. Its small size calls for careful interpretation.
People taking retatrutide lost weight in studies. Let us look at how much changed and what else matters.
Semaglutide is associated with injection pens. Newer research and European documents show what is also known about tablets. Important safety updates are appearing alongside these developments.
More studies are looking at what happens after the initial weight loss. A 2026 publication examines different ways of continuing treatment with tirzepatide.
News about a regulatory change or a small study may sound like a breakthrough. For BPC-157, it is worth checking exactly what it concerns.
Saying that thymosin beta-4 has been studied does not yet answer the question about TB-500. The exact molecule, route of administration and participants' health condition all matter.
A new registry entry shows which questions researchers want to investigate. It does not yet answer whether MOTS-c helps patients.
Small studies of a skin cream and an eyebrow serum appeared in 2026. They are worth knowing about, but should not be treated as evidence of broad anti-ageing effects.
Longevity is sometimes used to describe very different outcomes. Check whether the study assessed human lifespan, animal performance or a single measurement in a cell.
No articles match the selected filters.